Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Youyi Fong

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
Plos One|July 6, 2019
Point-of-care CD4 technology invalid result rates in public health care settings across five countriesKatherine Lamp, Seth McGovern, Youyi Fong, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Journal of Virology|May 10, 2013
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccineesPinghuang Liu, Nicole L Yates, Xiaoying Shen, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Journal of Virology|August 23, 2019
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine TrialShuying S Li, Peter B Gilbert, Lindsay N Carpp, et al.
The Journal of Infectious Diseases|December 8, 2017
A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous InoculationSean C Murphy, Elizabeth R Duke, Kelly J Shipman, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Plos One|February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infectionSusan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Plos One|July 6, 2019
Point-of-care CD4 technology invalid result rates in public health care settings across five countriesKatherine Lamp, Seth McGovern, Youyi Fong, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2013
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgGGeorgia D Tomaras, Guido Ferrari, Xiaoying Shen, et al.
Journal of Virology|May 10, 2013
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccineesPinghuang Liu, Nicole L Yates, Xiaoying Shen, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Journal of Virology|August 23, 2019
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine TrialShuying S Li, Peter B Gilbert, Lindsay N Carpp, et al.
The Journal of Infectious Diseases|December 8, 2017
A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous InoculationSean C Murphy, Elizabeth R Duke, Kelly J Shipman, et al.
Annals of Internal Medicine|October 22, 2020
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine TrialsDevan V Mehrotra, Holly E Janes, Thomas R Fleming, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2020
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Plos One|February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infectionSusan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Pageof 11